Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating the negative impact of integrase inhibitor-based antiretroviral therapy in early pregnancy

FY 2021-22

Summary
It is recommended that HIV-positive (HIV+) women take a specific type of HIV medication, antiretroviral therapy (ART), during their pregnancy. ART is made-up of a combination of drugs, each targeting different steps of HIVs replication cycle in the human body. As a result, ART is excellent at keeping moms healthy and eliminating the risk of HIV transmission to the baby. Although ART is widely used, there is a growing concern of potential side effects on the unborn baby when taken during pregnancy, such as miscarriage, preterm birth, and a low-birth-weight baby. We dont yet fully understand how ART causes these side effects, or which specific components of ART have the fewest side effects when taken during pregnancy. Our lab has shown that older ART drug components, the protease inhibitors, lower the levels of progesterone, the well-known ;pregnancy hormone, in HIV+ pregnant women. Progesterone is important in establishing and maintaining pregnancy. Very early in pregnancy, the maternal side of the placenta, termed the decidua, must form first and relies on progesterone to form properly. If progesterone levels are lowered by certain components of ART, the decidua may not form correctly, possibly affecting the quality of the placenta and the outcome of the pregnancy. We do not yet know if newer ART drug components, the integrase inhibitors, negatively affect pregnancy. To examine this, we will investigate how integrase inhibitors affect the formation and function of the decidua doing experiments on human decidual and placental tissue and in a mouse pregnancy model. Our findings will inform the selection of the safest integrase inhibitors to use as components of ART in pregnancy, with the ultimate goal of improving pregnancy outcome.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466670
Name
Acosta Sebastian
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the negative impact of integrase inhibitor-based antiretroviral therapy in early pregnancy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antiretroviral Therapy; Birth Outcomes; Decidualization; Dolutegravir; Drug Safety; Hiv Antiretroviral Toxicity; Hiv Integrase Inhibitors; Human Pregnancy; Maternal Immunology; Spiral Artery Remodelling
Abstract
It is recommended that HIV-positive (HIV+) women take a specific type of HIV medication, antiretroviral therapy (ART), during their pregnancy. ART is made-up of a combination of drugs, each targeting different steps of HIVs replication cycle in the human body. As a result, ART is excellent at keeping moms healthy and eliminating the risk of HIV transmission to the baby. Although ART is widely used, there is a growing concern of potential side effects on the unborn baby when taken during pregnancy, such as miscarriage, preterm birth, and a low-birth-weight baby. We dont yet fully understand how ART causes these side effects, or which specific components of ART have the fewest side effects when taken during pregnancy. Our lab has shown that older ART drug components, the protease inhibitors, lower the levels of progesterone, the well-known ;pregnancy hormone, in HIV+ pregnant women. Progesterone is important in establishing and maintaining pregnancy. Very early in pregnancy, the maternal side of the placenta, termed the decidua, must form first and relies on progesterone to form properly. If progesterone levels are lowered by certain components of ART, the decidua may not form correctly, possibly affecting the quality of the placenta and the outcome of the pregnancy. We do not yet know if newer ART drug components, the integrase inhibitors, negatively affect pregnancy. To examine this, we will investigate how integrase inhibitors affect the formation and function of the decidua doing experiments on human decidual and placental tissue and in a mouse pregnancy model. Our findings will inform the selection of the safest integrase inhibitors to use as components of ART in pregnancy, with the ultimate goal of improving pregnancy outcome.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Acosta, Sebastian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~